Published in J Med Virol on June 01, 2013
Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol (2013) 1.69
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol (2014) 1.26
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet (2004) 5.27
Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med (2004) 2.84
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol (2006) 2.33
Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis (2007) 2.30
Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses (2002) 2.20
Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule". Clin Infect Dis (2004) 2.15
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology (2010) 2.13
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med (2010) 2.13
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med (2007) 1.99
Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev (2012) 1.95
Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood (2013) 1.77
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS (2009) 1.68
Improved detection of five major gastrointestinal pathogens by use of a molecular screening approach. J Clin Microbiol (2010) 1.50
Transmission networks of HIV-1 among men having sex with men in the Netherlands. AIDS (2010) 1.49
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS (2013) 1.42
Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol (2011) 1.42
[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. Ned Tijdschr Geneeskd (2013) 1.39
Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline. J Antimicrob Chemother (2011) 1.36
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology (2010) 1.34
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30
Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother (2011) 1.28
Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol (2010) 1.27
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
The sialylated lipooligosaccharide outer core in Campylobacter jejuni is an important determinant for epithelial cell invasion. Infect Immun (2008) 1.25
Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol (2009) 1.19
Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs (2003) 1.18
Eradication of carriage with methicillin-resistant Staphylococcus aureus: determinants of treatment failure. J Antimicrob Chemother (2011) 1.17
Clinical and molecular epidemiologic characteristics of coagulase-negative staphylococcal bloodstream infections in intensive care neonates. Pediatr Infect Dis J (2007) 1.16
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis (2010) 1.14
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog (2012) 1.13
Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size. J Clin Microbiol (2005) 1.12
Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog (2011) 1.09
Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother (2006) 1.09
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS (2008) 1.08
Coagulase-negative staphylococcal skin carriage among neonatal intensive care unit personnel: from population to infection. J Clin Microbiol (2010) 1.08
Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis (2006) 1.07
Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients. Scand J Infect Dis (2012) 1.07
Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants. Pediatrics (2008) 1.03
Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis (2009) 1.03
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis (2011) 1.02
Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology (2013) 1.01
Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis. J Clin Microbiol (2006) 1.01
5 years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect Control Hosp Epidemiol (2009) 0.99
An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs. J Acquir Immune Defic Syndr (2006) 0.99
Colonization and resistance dynamics of gram-negative bacteria in patients during and after hospitalization. Antimicrob Agents Chemother (2005) 0.99
Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis (2009) 0.98
Nasopharyngeal co-colonization with Staphylococcus aureus and Streptococcus pneumoniae in children is bacterial genotype independent. Microbiology (2007) 0.98
HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 0.98
Detection of methicillin-resistant Staphylococcus aureus in a low-prevalence setting by polymerase chain reaction with a selective enrichment broth. Diagn Microbiol Infect Dis (2008) 0.94
Chlamydia trachomatis and placental inflammation in early preterm delivery. Eur J Epidemiol (2011) 0.94
A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol (2011) 0.94
The potential for multidrug-resistant influenza. Curr Opin Infect Dis (2011) 0.93
Successful search-and-destroy policy for methicillin-resistant Staphylococcus aureus in The Netherlands. J Clin Microbiol (2005) 0.93
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther (2011) 0.92
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study. AIDS (2014) 0.91
Detection of Campylobacter species and Arcobacter butzleri in stool samples by use of real-time multiplex PCR. J Clin Microbiol (2012) 0.90
Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J Immunol (2006) 0.89
Staphylococcus aureus nasal carriage is not associated with known polymorphism in the Vitamin D receptor gene. FEMS Immunol Med Microbiol (2005) 0.88
Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. PLoS One (2013) 0.88
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir Ther (2012) 0.88
Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase. Retrovirology (2008) 0.85
Ruling out clinically suspected pulmonary embolism by assessment of clinical probability and D-dimer levels: a management study. Thromb Haemost (2003) 0.85
Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr (2014) 0.85
Nose picking and nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol (2006) 0.84
Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop. Antivir Ther (2008) 0.83
Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms. J Acquir Immune Defic Syndr (2011) 0.83
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology (2012) 0.82
Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations. J Mol Diagn (2013) 0.82
Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. J Infect Dis (2002) 0.82
Therapy failure resulting from superinfection by a drug-resistant HIV variant. Antivir Ther (2012) 0.81
Low cost HIV-1 quantitative RT-PCR assay in resource-limited settings: improvement and implementation. J Virol Methods (2012) 0.81
HIV protease resistance and viral fitness. Curr Opin HIV AIDS (2007) 0.81
Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase. Virology (2007) 0.81
A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity. PLoS One (2013) 0.80
Risk factors associated with Campylobacter jejuni infections in Curaçao, Netherlands Antilles. J Clin Microbiol (2003) 0.80
Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity. Antiviral Res (2007) 0.79
Costs and effects of screening and treating low risk women with a singleton pregnancy for asymptomatic bacteriuria, the ASB study. BMC Pregnancy Childbirth (2012) 0.79
Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008. Open Virol J (2011) 0.78
Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations. Antivir Ther (2008) 0.78
Tuberculosis mimicking ileocecal intussusception in a 5-month-old girl. Pediatrics (2008) 0.78
Cyanoacrylate skin microsealant for preventing surgical site infection after vascular surgery: a discontinued randomized clinical trial. Surg Infect (Larchmt) (2014) 0.78
Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein. J Virol (2007) 0.77
[Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient]. Ned Tijdschr Geneeskd (2010) 0.77
Ongoing HIV replication in cerebrospinal fluid under successful monotherapy. Antivir Ther (2013) 0.77
Consistency of epidemiologic estimates. Eur J Epidemiol (2005) 0.77
Moraxella catarrhalis is only a weak activator of the mannose-binding lectin (MBL) pathway of complement activation. FEMS Microbiol Lett (2005) 0.77
Virological failure and drug resistance during first line anti-retroviral treatment in Indonesia. J Med Virol (2013) 0.76
HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies. Antivir Ther (2011) 0.76
[MRSA carriership in families of MRSA patients]. Ned Tijdschr Geneeskd (2011) 0.75
Malaria Fever Therapy for General Paralysis of the Insane: A Historical Cohort Study. Eur Neurol (2017) 0.75
Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop. Antivir Ther (2009) 0.75
Clinical Presentation of General Paralysis of the Insane in a Dutch Psychiatric Hospital, 1924-1954. Eur Neurol (2015) 0.75
Unite forces to validate biomarkers in the quest for lasting HIV remission. AIDS (2016) 0.75
[When to carry out contact investigations in shigellosis: no need for extensive contact investigations in solitary cases]. Ned Tijdschr Geneeskd (2015) 0.75